ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Lactate Metabolism and Protein Lactylation in Diabetic Kidney Disease: A Narrative Review.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Kidney Disease (DKD) is one of the common and serious microvascular complications of diabetes, and the pathogenesis is complex and incompletely understood. Recent studies have shown that lactylation, as a novel form of protein post-translational modification, has been increasingly involved in the progression of DKD through the specific binding of lactate molecules to protein amino acid residues, particularly involving important pathological processes such as inflammatory regulation, cell death-related signaling pathways and fibrotic remodeling. This review summarizes current evidence on abnormal lactate metabolism in DKD and the mechanisms by which lactate-driven lactylation regulates signaling pathways associated with kidney injury. It further evaluates the potential of lactate as a clinical biomarker and discusses intervention strategies targeting lactate metabolism as well as enzymes involved in lactylation and delactylation. These findings provide new insights and future research directions for the prevention and treatment of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.